Lonza Group AG
LONN
Classement en actions
#447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Prix de l'action
$764.04
Capitalisation boursière
$53.36B
Changement (1 jour)
0.96%
Changement (1 an)
8.59%
Pays
CH
Échange Lonza Group AG (LONN)
Catégorie
Healthcare
Revenus pour Lonza Group AG (LONN)
Revenus en Oct 2026 TTM : 0
Selon les derniers rapports financiers de Lonza Group AG, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Lonza Group AG de 2004 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2025 | $8.23B | 35.66% |
| 2024 | $6.07B | -24.04% |
| 2023 | $7.99B | 18.66% |
| 2022 | $6.73B | 13.45% |
| 2021 | $5.93B | 18.22% |
| 2020 | $5.02B | 15.40% |
| 2019 | $4.35B | -22.81% |
| 2018 | $5.63B | 20.73% |
| 2017 | $4.67B | 14.94% |
| 2016 | $4.06B | 6.70% |
| 2015 | $3.80B | 3.83% |
| 2014 | $3.66B | -8.77% |
| 2013 | $4.02B | -6.34% |
| 2012 | $4.29B | 49.65% |
| 2011 | $2.87B | -0.07% |
| 2010 | $2.87B | 10.16% |
| 2009 | $2.60B | -5.33% |
| 2008 | $2.75B | 8.28% |
| 2007 | $2.54B | 35.49% |
| 2006 | $1.87B | 30.23% |
| 2005 | $1.44B | -25.02% |
| 2004 | $1.92B | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| $10.11B | - |
BE
|
